Acorai, a Swedish company focused on heart failure management devices, has secured €4.2 million in funding from the European Innovation Council and private investors to advance clinical trials and regulatory approvals in the U.S. and Europe. The company is developing a noninvasive intracardiac pressure monitoring device, leveraging its patented SAVE Sensor System, and aims for a commercial launch by 2026, potentially benefiting over 60 million heart failure patients globally.